Aquestive Therapeutics, Inc.
(NASDAQ : AQST)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson
-0.36%145.380.6%$1129.21m
MRKMerck & Co., Inc.
-2.12%76.710.6%$1006.42m
PFEPfizer Inc.
-2.35%43.930.9%$997.18m
ABBVAbbVie, Inc.
-3.75%86.942.2%$612.33m
LLYEli Lilly and Company
-1.95%113.581.0%$522.64m
BMYBristol-Myers Squibb Company
-0.32%53.081.4%$462.56m
NVSNovartis AG Sponsored ADR
-2.24%87.060.2%$235.59m
AZNAstraZeneca PLC Sponsored ADR
-1.78%38.181.3%$201.57m
GSKGlaxoSmithKline plc Sponsored ADR
-0.37%37.280.2%$135.92m
NVONovo Nordisk A/S Sponsored ADR Class B
-0.57%45.380.1%$62.68m
SNYSanofi Sponsored ADR
-0.55%43.470.2%$42.50m
LCILannett Company, Inc.
-1.65%5.3737.0%$12.19m
AKTXAkari Therapeutics Plc Sponsored ADR
1.11%1.821.7%$0.03m
EPIXESSA Pharma Inc
-13.07%2.300.1%$0.00m

Company Profile

Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing differentiated products to address unmet medical needs. The company has a late-stage proprietary product pipeline focused on the treatment of Central nervous system (CNS) diseases, as well as orally-administered complex molecules that can be alternatives to invasively-administered standard of care therapies. Its product candidates include Libervant, Sympazan, and AQST-117 (Riluzole). Aquestive Therapeutics develops and delivers drugs via its PharmFilm® technology. The company also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. In addition to its proprietary product candidates, the company, with its partners, has a portfolio of development-stage products and commercialized products, such as Suboxone, a prescription medicine for the treatment of opioid dependence. The company was founded in January 2004 and is headquartered in Warren, NJ.